Skip to main content
Top

11-05-2018 | Axial spondyloarthritis | Review | Article

Axial disease in psoriatic arthritis and ankylosing spondylitis: a critical comparison

Journal: Nature Reviews Rheumatology

Authors: Joy Feld, Vinod Chandran, Nigil Haroon, Robert Inman, Dafna Gladman

Publisher: Nature Publishing Group UK

Abstract

Ankylosing spondylitis (AS) was first identified in the late 17th century. 250 years later, inflammatory spine disease was recognized to be one of the patterns of psoriatic arthritis (PsA). Isolated spondylitis is rare among patients with PsA, occurring in less than 5% of patients; however, many patients with PsA have axial disease that is concurrent with peripheral arthritis. At the other end of the spondyloarthritis spectrum, psoriasis is observed in 10% of patients with AS. Although axial involvement in PsA can be indistinguishable from axial disease in AS, it can also differ in several respects, raising the question of whether axial PsA and AS (with or without psoriasis) are different clinical presentations of the same disease, or whether they are separate diseases that have overlapping features. In this Review, the clinical presentation, metrology, radiographic characteristics, genetic factors, treatment options and axial prognosis of the two diseases are addressed. The aim of this Review is to capture all available comparisons made to date, to highlight the similarities and differences between AS and axial PsA and to propose a research agenda.
Literature
1.
Rudwaleit, M. et al. The assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann. Rheum. Dis. 70, 25–31 (2011).PubMedCrossRef
2.
van der Linden, S. M., Valkenburg, H. A., de Jongh, B. M. & Cats, A. The risk of developing ankylosing spondylitis in HLA-B27 positive individuals. A comparison of relatives of spondylitis patients with the general population. Arthritis Rheum. 27, 241–249 (1984).PubMedCrossRef
3.
Taurog, J. D., Chhabra, A. & Colbert, R. A. Ankylosing spondylitis and axial spondyloarthritis. N. Engl. J. Med. 374, 2563–2574 (2016).PubMedCrossRef
4.
Moll, J. M. & Wright, V. Psoriatic arthritis. Semin. Arthritis Rheum. 3, 55–78 (1973).PubMedCrossRef
5.
Ritchlin, C. T. et al. Treatment recommendations for psoriatic arthritis. Ann. Rheum. Dis. 68, 1387–1394 (2009).PubMedCrossRef
6.
Taylor, W. J., Zmierczak, H. G. & Helliwell, P. S. Problems with the definition of axial and peripheral disease patterns in psoriatic arthritis. J. Rheumatol. 32, 974–977 (2005).PubMed
7.
Gladman, D. D. Axial disease in psoriatic arthritis. Curr. Rheumatol. Rep. 9, 455–460 (2007).PubMedCrossRef
8.
Chandran, V., Tolusso, D. C., Cook, R. J. & Gladman, D. D. Risk factors for axial inflammatory arthritis in patients with psoriatic arthritis. J. Rheumatol. 37, 809–815 (2010).PubMedCrossRef
9.
Baraliakos, X., Coates, L. C. & Braun, J. The involvement of the spine in psoriatic arthritis. Clin. Exp. Rheumatol. 33, S31–35 (2015).PubMed
10.
Torre Alonso, J. C. et al. Psoriatic arthritis (PA): a clinical, immunological and radiological study of 180 patients. Br. J. Rheumatol. 30, 245–250 (1991).PubMedCrossRef
11.
Yang, Q. et al. Prevalence and characteristics of psoriatic arthritis in Chinese patients with psoriasis. J. Eur. Acad. Dermatol. Venereol. 25, 1409–1414 (2011).PubMedCrossRef
12.
Moghaddassi, M., Shahram, F., Chams-Davatchi, C., Najafizadeh, S. R. & Davatchi, F. Different aspects of psoriasis: analysis of 150 Iranian patients. Arch. Iran. Med. 12, 279–283 (2009).PubMed
13.
Coates, L. C. et al. Sensitivity and specificity of the classification of psoriatic arthritis criteria in early psoriatic arthritis. Arthritis Rheum. 64, 3150–3155 (2012).PubMedCrossRef
14.
Niccoli, L. et al. Frequency of iridocyclitis in patients with early psoriatic arthritis: a prospective, follow up study. Int. J. Rheum. Dis. 15, 414–418 (2012).PubMedCrossRef
15.
Nossent, J. C. & Gran, J. T. Epidemiological and clinical characteristics of psoriatic arthritis in northern Norway. Scand. J. Rheumatol. 38, 251–255 (2009).PubMedCrossRef
16.
van der Linden, S., Valkenburg, H. A. & Cats, A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 27, 361–368 (1984).PubMedCrossRef
17.
Chandran, V., Barrett, J., Schentag, C. T., Farewell, V. T. & Gladman, D. D. Axial psoriatic arthritis: update on a longterm prospective study. J. Rheumatol. 36, 2744–2750 (2009).PubMedCrossRef
18.
Hanly, J. G., Russell, M. L. & Gladman, D. D. Psoriatic spondyloarthropathy: a long term prospective study. Ann. Rheum. Dis. 47, 386–393 (1988).PubMedPubMedCentralCrossRef
19.
Queiro, R. et al. Clinically asymptomatic axial disease in psoriatic spondyloarthropathy. A retrospective study. Clin. Rheumatol. 21, 10–13 (2002).PubMedCrossRef
20.
Gladman, D. D., Brubacher, B., Buskila, D., Langevitz, P. & Farewell, V. T. Differences in the expression of spondyloarthropathy: a comparison between ankylosing spondylitis and psoriatic arthritis. Clin. Invest. Med. 16, 1–7 (1993).PubMed
21.
Lubrano, E. et al. The definition and measurement of axial psoriatic arthritis. J. Rheumatol. Suppl. 93, 40–42 (2015).PubMedCrossRef
22.
Lubrano, E. & Spadaro, A. Axial psoriatic arthritis: an intriguing clinical entity or a subset of an intriguing disease? Clin. Rheumatol. 31, 1027–1032 (2012).PubMedCrossRef
23.
Jadon, D. R. et al. Axial disease in psoriatic arthritis study: defining the clinical and radiographic phenotype of psoriatic spondyloarthritis. Ann. Rheum. Dis. 76, 701–707 (2017).PubMedCrossRef
24.
Exarchou, S. et al. The prevalence of clinically diagnosed ankylosing spondylitis and its clinical manifestations: a nationwide register study. Arthritis Res. Ther. 17, 118 (2015).PubMedPubMedCentralCrossRef
25.
Cortes, A. et al. Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci. Nat. Genet. 45, 730–738 (2013).PubMedPubMedCentralCrossRef
26.
O’Rielly, D. D., Uddin, M. & Rahman, P. Ankylosing spondylitis: beyond genome-wide association studies. Curr. Opin. Rheumatol. 28, 337–345 (2016).PubMedCrossRef
27.
Brown, M. A., Kenna, T. & Wordsworth, B. P. Genetics of ankylosing spondylitis — insights into pathogenesis. Nat. Rev. Rheumatol. 12, 81–91 (2016).PubMedCrossRef
28.
Wordsworth, P. Genes in the spondyloarthropathies. Rheum. Dis. Clin. North Am. 24, 845–863 (1998).PubMedCrossRef
29.
Uddin, M. et al. Integrated genomics identifies convergence of ankylosing spondylitis with global immune mediated disease pathways. Sci. Rep. 5, 10314 (2015).PubMedPubMedCentralCrossRef
30.
Essers, I. et al. Characteristics associated with the presence and development of extra-articular manifestations in ankylosing spondylitis: 12-year results from OASIS. Rheumatology 54, 633–640 (2015).PubMedCrossRef
31.
Machado, P. et al. Ankylosing spondylitis patients with and without psoriasis do not differ in disease phenotype. Ann. Rheum. Dis. 72, 1104–1107 (2013).PubMedCrossRef
32.
Parkes, M., Cortes, A., van Heel, D. A. & Brown, M. A. Genetic insights into common pathways and complex relationships among immune-mediated diseases. Nat. Rev. Genet. 14, 661–673 (2013).PubMedCrossRef
33.
Chandran, V. & Raychaudhuri, S. P. Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis. J. Autoimmun. 34, J314–321 (2010).PubMedCrossRef
34.
Ritchlin, C. T., Colbert, R. A. & Gladman, D. D. Psoriatic Arthritis. N. Engl. J. Med. 376, 957–970 (2017).PubMedCrossRef
35.
Ananthakrishnan, R., Eckes, L. & Walter, H. On the genetics of psoriasis. An analysis of Hellgren’s data for a model of multifactorial inheritance. Arch. Dermatol. Forsch. 247, 53–58 (1973).PubMedCrossRef
36.
Brandrup, F., Holm, N., Grunnet, N., Henningsen, K. & Hansen, H. E. Psoriasis in monozygotic twins: variations in expression in individuals with identical genetic constitution. Acta Derm. Venereol. 62, 229–236 (1982).PubMed
37.
Lonnberg, A. S. et al. Heritability of psoriasis in a large twin sample. Br. J. Dermatol. 169, 412–416 (2013).PubMedCrossRef
38.
Myers, A., Kay, L. J., Lynch, S. A. & Walker, D. J. Recurrence risk for psoriasis and psoriatic arthritis within sibships. Rheumatology 44, 773–776 (2005).PubMedCrossRef
39.
Chandran, V. et al. Familial aggregation of psoriatic arthritis. Ann. Rheum. Dis. 68, 664–667 (2009).PubMedCrossRef
40.
Karason, A., Love, T. J. & Gudbjornsson, B. A strong heritability of psoriatic arthritis over four generations — the Reykjavik Psoriatic Arthritis Study. Rheumatology 48, 1424–1428 (2009).PubMedCrossRef
41.
Winchester, R. et al. HLA associations reveal genetic heterogeneity in psoriatic arthritis and in the psoriasis phenotype. Arthritis Rheum. 64, 1134–1144 (2012).PubMedCrossRef
42.
Eder, L., Chandran, V. & Gladman, D. D. What have we learned about genetic susceptibility in psoriasis and psoriatic arthritis? Curr. Opin. Rheumatol. 27, 91–98 (2015).PubMedCrossRef
43.
Chandran, V. et al. Human leukocyte antigen alleles and susceptibility to psoriatic arthritis. Hum. Immunol. 74, 1333–1338 (2013).PubMedCrossRef
44.
Eder, L. et al. Human leucocyte antigen risk alleles for psoriatic arthritis among patients with psoriasis. Ann. Rheum. Dis. 71, 50–55 (2012).PubMedCrossRef
45.
Queiro, R. et al. HLA-C locus alleles may modulate the clinical expression of psoriatic arthritis. Arthritis Res. Ther. 8, R185 (2006).PubMedPubMedCentralCrossRef
46.
FitzGerald, O., Haroon, M., Giles, J. T. & Winchester, R. Concepts of pathogenesis in psoriatic arthritis: genotype determines clinical phenotype. Arthritis Res. Ther. 17, 115 (2015).PubMedPubMedCentralCrossRef
47.
Tang, H. et al. A large-scale screen for coding variants predisposing to psoriasis. Nat. Genet. 46, 45–50 (2014).PubMedCrossRef
48.
Ellinghaus, E. et al. Genome-wide association study identifies a psoriasis susceptibility locus at TRAF3IP2. Nat. Genet. 42, 991–995 (2010).PubMedPubMedCentralCrossRef
49.
Cargill, M. et al. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am. J. Hum. Genet. 80, 273–290 (2007).PubMedCrossRef
50.
Liu, Y. et al. A genome-wide association study of psoriasis and psoriatic arthritis identifies new disease loci. PLoS Genet. 4, e1000041 (2008).PubMedPubMedCentralCrossRef
51.
Huffmeier, U. et al. Common variants at TRAF3IP2 are associated with susceptibility to psoriatic arthritis and psoriasis. Nat. Genet. 42, 996–999 (2010).PubMedPubMedCentralCrossRef
52.
Ellinghaus, E. et al. Genome-wide meta-analysis of psoriatic arthritis identifies susceptibility locus at REL. J. Invest. Dermatol. 132, 1133–1140 (2012).PubMedCrossRef
53.
Stuart, P. E. et al. Genome-wide association analysis of psoriatic arthritis and cutaneous psoriasis reveals differences in their genetic architecture. Am. J. Hum. Genet. 97, 816–836 (2015).PubMedPubMedCentralCrossRef
54.
Lanier, L. L. NK cell recognition. Annu. Rev. Immunol. 23, 225–274 (2005).PubMedCrossRef
55.
Chandran, V. et al. Killer-cell immunoglobulin-like receptor gene polymorphisms and susceptibility to psoriatic arthritis. Rheumatology 53, 233–239 (2014).PubMedCrossRef
56.
Weisman, M. H., Witter, J. P. & Reveille, J. D. The prevalence of inflammatory back pain: population-based estimates from the US National Health and Nutrition Examination Survey, 2009–2010. Ann. Rheum. Dis. 72, 369–373 (2013).PubMedCrossRef
57.
Mease, P. J., Garg, A., Helliwell, P. S., Park, J. J. & Gladman, D. D. Development of criteria to distinguish inflammatory from noninflammatory arthritis, enthesitis, dactylitis, and spondylitis: a report from the GRAPPA 2013 annual meeting. J. Rheumatol. 41, 1249–1251 (2014).PubMedCrossRef
58.
Queiro, R. et al. Clinical expression, but not disease outcome, may vary according to age at disease onset in psoriatic spondylitis. Joint Bone Spine 75, 544–547 (2008).PubMedCrossRef
59.
Helliwell, P. S., Hickling, P. & Wright, V. Do the radiological changes of classic ankylosing spondylitis differ from the changes found in the spondylitis associated with inflammatory bowel disease, psoriasis, and reactive arthritis? Ann. Rheum. Dis. 57, 135–140 (1998).PubMedPubMedCentralCrossRef
60.
Lindstrom, U. et al. Back pain and health status in patients with clinically diagnosed ankylosing spondylitis, psoriatic arthritis and other spondyloarthritis: a cross-sectional population-based study. BMC Musculoskelet. Disord. 17, 106 (2016).PubMedPubMedCentralCrossRef
61.
Perez Alamino, R. et al. Differential features between primary ankylosing spondylitis and spondylitis associated with psoriasis and inflammatory bowel disease. J. Rheumatol. 38, 1656–1660 (2011).PubMedCrossRef
62.
Gladman, D. D., Brubacher, B., Buskila, D., Langevitz, P. & Farewell, V. T. Psoriatic spondyloarthropathy in men and women: a clinical, radiographic, and HLA study. Clin. Invest. Med. 15, 371–375 (1992).PubMed
63.
Landi, M. et al. Gender differences among patients with primary ankylosing spondylitis and spondylitis associated with psoriasis and inflammatory bowel disease in an iberoamerican spondyloarthritis cohort. Medicine 95, e5652 (2016).PubMedPubMedCentralCrossRef
64.
Gladman, D. D. et al. International spondyloarthritis interobserver reliability exercise — the INSPIRE study: I. Assessment of spinal measures. J. Rheumatol. 34, 1733–1739 (2007).PubMed
65.
Helliwell, P. S. Assessment of disease activity in psoriatic arthritis. Clin. Exp. Rheumatol. 33, S44–S47 (2015).PubMed
66.
Taylor, W. J. & Harrison, A. A. Could the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) be a valid measure of disease activity in patients with psoriatic arthritis? Arthritis Rheum. 51, 311–315 (2004).PubMedCrossRef
67.
Fernandez-Sueiro, J. L. et al. Validity of the Bath Ankylosing Spondylitis Disease Activity Index for the evaluation of disease activity in axial psoriatic arthritis. Arthritis Care Res. 62, 78–85 (2010).CrossRef
68.
Orbai, A. M. et al. International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials. Ann. Rheum. Dis. 76, 673–680 (2017).PubMedCrossRef
69.
Eder, L., Chandran, V., Shen, H., Cook, R. J. & Gladman, D. D. Is ASDAS better than BASDAI as a measure of disease activity in axial psoriatic arthritis? Ann. Rheum. Dis. 69, 2160–2164 (2010).PubMedCrossRef
70.
Turkiewicz, A. M. & Moreland, L. W. Psoriatic arthritis: current concepts on pathogenesis-oriented therapeutic options. Arthritis Rheum. 56, 1051–1066 (2007).PubMedCrossRef
71.
MacKay, K., Mack, C., Brophy, S. & Calin, A. The Bath Ankylosing Spondylitis Radiology Index (BASRI): a new, validated approach to disease assessment. Arthritis Rheum. 41, 2263–2270 (1998).PubMedCrossRef
72.
Averns, H. L. et al. Radiological outcome in ankylosing spondylitis: use of the Stoke Ankylosing Spondylitis Spine Score (SASSS). Br. J. Rheumatol. 35, 373–376 (1996).PubMedCrossRef
73.
Creemers, M. C. et al. Assessment of outcome in ankylosing spondylitis: an extended radiographic scoring system. Ann. Rheum. Dis. 64, 127–129 (2005).PubMedCrossRef
74.
Lubrano, E. et al. Psoriatic Arthritis Spondylitis Radiology Index: a modified index for radiologic assessment of axial involvement in psoriatic arthritis. J. Rheumatol. 36, 1006–1011 (2009).PubMedCrossRef
75.
Baraliakos, X., Listing, J., Rudwaleit, M., Sieper, J. & Braun, J. Development of a radiographic scoring tool for ankylosing spondylitis only based on bone formation: addition of the thoracic spine improves sensitivity to change. Arthritis Rheum. 61, 764–771 (2009).PubMedCrossRef
76.
Biagioni, B. J. et al. Reliability of radiographic scoring methods in axial psoriatic arthritis. Arthritis Care Res. 66, 1417–1422 (2014).CrossRef
77.
Lubrano, E. et al. The radiological assessment of axial involvement in psoriatic arthritis: a validation study of the BASRI total and the modified SASSS scoring methods. Clin. Exp. Rheumatol. 27, 977–980 (2009).PubMed
78.
Rudwaleit, M. et al. The development of Assessment of SpondyloArthritis International Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal. Ann. Rheum. Dis. 68, 770–776 (2009).PubMedCrossRef
79.
Rudwaleit, M. et al. The development of Assessment of SpondyloArthritis International Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann. Rheum. Dis. 68, 777–783 (2009).PubMedCrossRef
80.
Richette, P. et al. Psoriasis and phenotype of patients with early inflammatory back pain. Ann. Rheum. Dis. 72, 566–571 (2013).PubMedCrossRef
81.
Poggenborg, R. P., Sorensen, I. J., Pedersen, S. J. & Ostergaard, M. Magnetic resonance imaging for diagnosing, monitoring and prognostication in psoriatic arthritis. Clin. Exp. Rheumatol. 33, S66–S69 (2015).PubMed
82.
Williamson, L. et al. Clinical assessment of sacroiliitis and HLA-B27 are poor predictors of sacroiliitis diagnosed by magnetic resonance imaging in psoriatic arthritis. Rheumatology 43, 85–88 (2004).PubMedCrossRef
83.
Ostergaard, M., Poggenborg, R. P., Axelsen, M. B. & Pedersen, S. J. Magnetic resonance imaging in spondyloarthritis — how to quantify findings and measure response. Best Pract. Res. Clin. Rheumatol. 24, 637–657 (2010).PubMedCrossRef
84.
Maldonado-Ficco, H., Sheane, B. J., Thavaneswaran, A., Chandran, V. & Gladman, D. D. Magnetic resonance imaging in psoriatic arthritis: a descriptive study of indications, features and effect on treatment change. J. Clin. Rheumatol. 23, 243–245 (2017).PubMedCrossRef
85.
Queiro, R., Tejon, P., Alonso, S., Alperi, M. & Ballina, J. Erosive discovertebral lesion (Andersson lesion) as the first sign of disease in axial psoriatic arthritis. Scand. J. Rheumatol. 42, 220–225 (2013).PubMedCrossRef
86.
Castillo-Gallego, C., Aydin, S. Z., Emery, P., McGonagle, D. G. & Marzo-Ortega, H. Magnetic resonance imaging assessment of axial psoriatic arthritis: extent of disease relates to HLA-B27. Arthritis Rheum. 65, 2274–2278 (2013).PubMedCrossRef
87.
Poggenborg, R. P. et al. Head-to-toe whole-body MRI in psoriatic arthritis, axial spondyloarthritis and healthy subjects: first steps towards global inflammation and damage scores of peripheral and axial joints. Rheumatology 54, 1039–1049 (2015).PubMedCrossRef
88.
Braun, J. et al. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann. Rheum. Dis. 70, 896–904 (2011).PubMedPubMedCentralCrossRef
89.
Rohekar, S. et al. 2014 update of the Canadian Rheumatology Association/Spondyloarthritis Research Consortium of Canada treatment recommendations for the management of spondyloarthritis. Part I: principles of the management of spondyloarthritis in Canada. J. Rheumatol. 42, 654–664 (2015).PubMedCrossRef
90.
Ward, M. M. et al. American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis Care Res. 68, 151–166 (2016).CrossRef
91.
Sieper, J. et al. Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 Study. Ann. Rheum. Dis. 76, 571–592 (2017).PubMedCrossRef
92.
Mease, P. J. et al. Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis. N. Engl. J. Med. 373, 1329–1339 (2015).PubMedCrossRef
93.
Strand, V. et al. Secukinumab improves patient-reported outcomes in subjects with active psoriatic arthritis: results from a randomised phase III trial (FUTURE 1). Ann. Rheum. Dis. 76, 203–207 (2017).PubMedCrossRef
94.
Mease, P. & McInnes, I. B. Secukinumab: a new treatment option for psoriatic arthritis. Rheumatol. Ther. 3, 5–29 (2016).PubMedPubMedCentralCrossRef
95.
US National Library of Medicine. ClinicalTrials.gov https://​clinicaltrials.​gov/​ct2/​show/​NCT02721966 (2017).
96.
Poddubnyy, D., Hermann, K. G., Callhoff, J., Listing, J. & Sieper, J. Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS). Ann. Rheum. Dis. 73, 817–823 (2014).PubMedCrossRef
97.
Yeremenko, N., Paramarta, J. E. & Baeten, D. The interleukin-23/interleukin-17 immune axis as a promising new target in the treatment of spondyloarthritis. Curr. Opin. Rheumatol. 26, 361–370 (2014).PubMedCrossRef
98.
Baeten, D. et al. Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. N. Engl. J. Med. 373, 2534–2548 (2015).PubMedCrossRef
99.
Pathan, E. et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in ankylosing spondylitis. Ann. Rheum. Dis. 72, 1475–1480 (2013).PubMedCrossRef
100.
US National Library of Medicine. ClinicalTrials.gov https://​clinicaltrials.​gov/​ct2/​show/​NCT01583374 (2018).
101.
van der Heijde, D. et al. Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study. Ann. Rheum. Dis. 76, 1340–1347 (2017).PubMedPubMedCentralCrossRef
102.
Coates, L. C. et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheumatol. 68, 1060–1071 (2016).PubMed
103.
Gossec, L. et al. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann. Rheum. Dis. 75, 499–510 (2016).PubMedCrossRef
104.
Nash, P. et al. Updated guidelines for the management of axial disease in psoriatic arthritis. J. Rheumatol. 41, 2286–2289 (2014).PubMedCrossRef
105.
Mease, P. J. et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum. 50, 2264–2272 (2004).PubMedCrossRef
106.
Mease, P. J. et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 52, 3279–3289 (2005).PubMedCrossRef
107.
Mease, P. J. et al. Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis. N. Engl. J. Med. 370, 2295–2306 (2014).PubMedCrossRef
108.
Antoni, C. E. et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum. 52, 1227–1236 (2005).PubMedCrossRef
109.
Kavanaugh, A. et al. Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study). Ann. Rheum. Dis. 73, 1689–1694 (2014).PubMedPubMedCentralCrossRef
110.
Kavanaugh, A. et al. Radiographic progression of patients with psoriatic arthritis who achieve minimal disease activity in response to golimumab therapy: results through 5 years of a randomized, placebo-controlled study. Arthritis Care Res. 68, 267–274 (2016).CrossRef
111.
Gladman, D. D. et al. Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial. Arthritis Rheum. 56, 476–488 (2007).PubMedCrossRef
112.
McInnes, I. B. et al. Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial. Ann. Rheum. Dis. 73, 349–356 (2014).PubMedCrossRef
113.
Lubrano, E., Parsons, W. J. & Perrotta, F. M. Assessment of response to treatment, remission, and minimal disease activity in axial psoriatic arthritis treated with tumor necrosis factor inhibitors. J. Rheumatol. 43, 918–923 (2016).PubMedCrossRef
114.
Lubrano, E. et al. The effectiveness of a biologic agent on axial manifestations of psoriatic arthritis. A twelve months observational study in a group of patients treated with etanercept. Clin. Exp. Rheumatol. 29, 80–84 (2011).PubMed
115.
Maharaj, A. B. & Chandran, V. Treatment of psoriatic arthritis with traditional DMARD’s and novel therapies: approaches and recommendations. Expert Rev. Clin. Immunol. 13, 319–331 (2017).PubMedCrossRef
116.
Raychaudhuri, S. P., Wilken, R., Sukhov, A. C., Raychaudhuri, S. K. & Maverakis, E. Management of psoriatic arthritis: early diagnosis, monitoring of disease severity and cutting edge therapies. J. Autoimmun. 76, 21–37 (2017).PubMedCrossRef
117.
Gladman, D. et al. Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors. N. Engl. J. Med. 377, 1525–1536 (2017).PubMedCrossRef
118.
Carette, S., Graham, D., Little, H., Rubenstein, J. & Rosen, P. The natural disease course of ankylosing spondylitis. Arthritis Rheum. 26, 186–190 (1983).PubMedCrossRef
119.
Kaprove, R. E., Little, A. H., Graham, D. C. & Rosen, P. S. Ankylosing spondylitis: survival in men with and without radiotherapy. Arthritis Rheum. 23, 57–61 (1980).PubMedCrossRef
120.
Machado, P. et al. Both structural damage and inflammation of the spine contribute to impairment of spinal mobility in patients with ankylosing spondylitis. Ann. Rheum. Dis. 69, 1465–1470 (2010).PubMedCrossRef
121.
Poddubnyy, D. & Sieper, J. Radiographic progression in ankylosing spondylitis/axial spondyloarthritis: how fast and how clinically meaningful? Curr. Opin. Rheumatol. 24, 363–369 (2012).PubMedCrossRef
122.
van der Heijde, D. et al. Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. Arthritis Rheum. 58, 3063–3070 (2008).PubMedCrossRef
123.
van der Heijde, D. et al. Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum. 58, 1324–1331 (2008).PubMedCrossRef
124.
van der Heijde, D. et al. Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial. Ann. Rheum. Dis. 68, 922–929 (2009).PubMedCrossRef
125.
Haroon, N. et al. The impact of tumor necrosis factor alpha inhibitors on radiographic progression in ankylosing spondylitis. Arthritis Rheum. 65, 2645–2654 (2013).PubMedPubMedCentral
126.
Molnar, C. et al. TNF blockers inhibit spinal radiographic progression in ankylosing spondylitis by reducing disease activity: results from the Swiss Clinical Quality Management cohort. Ann. Rheum. Dis. 77, 63–69 (2018).PubMedCrossRef